Related Experiment Video
Updated: Feb 21, 2026
Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
Published on: August 1, 2013
Nanoplex cluster-mediated synergistic modulation of dendritic cells and T cells amplifies tumor-specific adaptive
Wei Mao1, Yeonju Park2, Songrae Kim3
1Department of Biomedical Materials Engineering, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea; Institute for Molecular Science and Fusion Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.
Abstract:
Tumor immune evasion is greatly impacted by immune checkpoint molecules that impede the activation of costimulatory signals. Inadequate costimulatory molecules restrict the immune system's capacity to generate strong responses to malignancies. This study presents a development of a dual-nanoplex cluster (NC) formulation that effectively overcomes these issues. The formulation comprises a nanoplex (NP) encapsulating CpG ODN 1826 (CpG NP), which stimulates TLR-9 and elevates the levels of CD80/86 costimulatory molecules on antigen-presenting cells, and a NP incorporating CTLA-4 siRNA (siCTLA-4 NP), which suppresses the production of the immunological checkpoint molecule CTLA-4 on T cells. The two NPs undergo a cycloaddition reaction involving azide groups (AZ) on the NPs and alkyne groups at both termini of an MMP-2-cleavable peptide (APA) to produce a NC. The NC formation process is modulated to fabricate a flexible and deformable architecture with optimized size that maximizes passive melanoma accumulation while maintaining systemic stability, exhibiting intratumoral cleavability and substantial tumor suppression efficacy. Ex-vivo study of cell composition in spleens and tumors, along with tumor-specific antigen stimulation assays on splenocytes, suggests that NC treatment can switch the immunosuppressive tumor microenvironment into an immunocompetent state. These findings demonstrate that our NC formulation, which integrates CTLA-4 suppression with DC stimulation, potentiates immune responses against tumor tissues, providing novel insights and potential applications in the field of cancer immunotherapy.
Insights
This study developed a dual-nanoplex cluster to enhance anti-tumor immunity by stimulating antigen-presenting cells and suppressing immune checkpoints. This approach converts the immunosuppressive tumor microenvironment into an immunocompetent state for effective cancer immunotherapy.
Area of Science:
- Immunology
- Nanotechnology
- Cancer Research
Background:
- Tumor immune evasion is a major challenge in cancer therapy, often caused by immune checkpoint molecules hindering T-cell activation.
- Insufficient costimulatory signals limit the immune system's ability to mount effective anti-cancer responses, contributing to tumor growth and metastasis.
Purpose of the Study:
- To develop a novel dual-nanoplex cluster (NC) formulation for cancer immunotherapy.
- To overcome tumor immune evasion by simultaneously stimulating costimulatory pathways and inhibiting immune checkpoints.
Main Methods:
- Formulation of a nanoplex (NP) with CpG ODN 1826 (CpG NP) to stimulate Toll-like receptor-9 (TLR-9) and upregulate CD80/86 costimulatory molecules.
- Development of a second NP with CTLA-4 siRNA (siCTLA-4 NP) to suppress cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) expression on T cells.
- Assembly of NPs into a dual-nanoplex cluster (NC) via a cycloaddition reaction, optimizing size and flexibility for tumor accumulation and stability.
Main Results:
- The NC formulation demonstrated efficient intratumoral cleavability and significant tumor suppression efficacy.
- Ex-vivo analysis showed NC treatment shifted the tumor microenvironment from immunosuppressive to immunocompetent.
- Splenocyte assays indicated enhanced anti-tumor immune responses following NC treatment.
Conclusions:
- The developed NC formulation effectively integrates CTLA-4 suppression with dendritic cell (DC) stimulation.
- This dual-action approach potentiates immune responses against tumors, offering a promising strategy for cancer immunotherapy.
- The findings provide novel insights into overcoming tumor immune evasion and enhancing cancer treatment outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...